HRTX HERON THERAPEUTICS, INC. /DE/ — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$0.43

Period return

-0.92 (-68.15%)

Volume

4.4M

2026-06-05O $0.48 H $0.48 L $0.42 C $0.43MA5 $0.53MA20 $0.81MA60 $0.91MA120 $1.09

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 01. 10.LowBUY5 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 08. 09.LowBUY10 months ago
Needham: Buy
US analyst rating / recommendation change.
2025. 06. 09.MediumBUY12 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $3.67 · 3 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.

Sector: Healthcare

HERON THERAPEUTICS, INC. /DE/

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 01. 10.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 08. 09.	Needham	—	Maintain	Buy → Buy	—	Needham: Buy
2025. 06. 09.	HC Wainwright & Co.	—	Initiate coverage	— → Buy	—	HC Wainwright & Co.: Buy
2025. 04. 11.	Needham	—	Maintain	Buy → Buy	—	Needham: Buy
2025. 02. 28.	Needham	—	Maintain	Buy → Buy	—	Needham: Buy
2024. 12. 04.	Needham	—	Maintain	Buy → Buy	—	Needham: Buy